Provider of high-performance life science solutions Molecular Devices has celebrated the one-year anniversary of its automated 3D imaging workcell, the Organoid Innovation Center with the expansion of new cell engineering capabilities.
Located at the company’s global headquarters, the Organoid Innovation Center helps researchers automate sample prep and screening for assays performed on complex 3D biological models.
Now, the centre has added new cell engineering capabilities through the QPix 400 Series Microbial Colony Picker and the ClonePix 2 Mammalian Colony Picker. These capabilities now allow the centre to offer early cell line development and expands its methods and technologies to include automated workflows for synthetic biology, antibody discovery, and cell line development, in addition to those currently in place for automated organoid culturing and screening.
These newly incorporated instruments expand the centre’s downstream, 2D cell line development capabilities, while automation and intuitive scheduling software ensure seamless interaction with systems that support upstream 3D biology culturing and screening applications. The centre now helps ease the transition from 2D to 3D biology for researchers, speeding up a transformative future for therapeutic drug discovery and development.
The company is also aiming to add another imaging technology with multi-channel fluorescence for day zero monoclonality verification, and confirmation of CRISPR edits, for a wide range of cell and gene therapy applications.
“We’re on the cusp of a transformational era of genomic medicine and gene-edited cell and gene therapies as innovative technology and specialized knowledge become more mainstream, making personalized therapeutic research and development increasingly accessible to more scientists,” said Dan O’Connor, Vice President, Drug Discovery, Molecular Devices. “By incorporating our synthetic biology-focused technology into the Organoid Innovation Center, we’re driving expanded capabilities for our customers as the industry heads toward an industrialization of biology, where automated synthetic biology, cell line development, and 3D biology research converge.”
“As more cell and gene therapy products are approved by the US Food and Drug Administration and enter the clinical market, Molecular Devices is poised to offer an end-to-end solution for automated discovery and scaleup to support the next great Investigational New Drug candidate,” O’Connor concluded.